Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.
1. A nutrient formulation for oral ingestion comprising:
a. at least 3 mg of zeaxanthin where the zeaxanthin is present in the 3R-3R′ stereoisomer form and is substantially free of meso-zeaxanthin stereoisomers;
b. at least one tocopherol that provides anti-oxidant activity; and
c. vitamin C;
wherein the nutrient formulation is provided in the form of a foodstuff.
2. The nutrient formulation of claim 1 , wherein the nutrient formulation is provided in the form of a powder or a liquid that is added to a food or drink.
3. The nutrient formulation of claim 1 , wherein the foodstuff is one selected from the group consisting of snack foods, energy or nutrition bars and mixes, beverages, canned or pouched food, and condiments.
4. The nutrient formulation of claim 1 , further comprising zinc at a dosage that does not exceed 40 milligrams of elemental zinc.
5. The nutrient formulation of claim 1 , wherein the foodstuff is a ready-to-eat.
6. The nutrient formulation of claim 1 , further comprising lutein.
7. The nutrient formulation of claim 1 , wherein vitamin C is in the form of absorbic acid.
8. The nutrient formulation of claim 1 , further comprising at least one of lipoic acid and omega-3 fatty acids.
9. The nutrient formulation of claim 1 , wherein the daily dosage of zeaxanthin is at least 10 milligrams.
10. The nutrient formulation of claim 1 , wherein the nutrient formulation, when ingested, assists in reducing the harmful effect of blue light.
11. The nutrient formulation of claim 1 , wherein the nutrient formulation is present in a form that provides sustained release over a span of at least 3 hours following ingestion.
12. A nutrient formulation for oral ingestion for protecting a user's eyes from the harmful effect of blue light, the formulation comprising:
a. zeaxanthin that is present in the 3R-3R′ stereoisomer form and is substantially free of meso-zeaxanthin stereoisomers;
b. lutein;
c. vitamin C; and
d. mixed tocopherols;
wherein the nutrient formulation is provided in the form selected from the group consisting of capsules, tablets, liquids, and powders for oral ingestion.
13. The nutrient formulation of claim 12 , further comprising lipoic acid.
14. The nutrient formulation of claim 12 , further comprising omega-3 fatty acids that are derived from fish oil.
15. The nutrient formulation of claim 12 , wherein the nutrient formulation is present in a form that provides sustained release over a span of at least 3 hours following ingestion.
16. The nutrient formulation of claim 12 , wherein the daily dosage of zeaxanthin is at least 10 milligrams.
17. The nutrient formulation of claim 12 , wherein the formulation is in the form of capsules containing oily carrier materials.
18. The nutrient formulation of claim 12 , wherein the mixed tocopherols include vitamin E.
19. The nutrient formulation of claim 12 , further comprising plant-derived active agents comprising at least one of flavonoids, bioflavonoids, anthocyanins, plant polyphenolics, and phytonutrients.
20. The nutrient formulation of claim 12 , further comprising zinc at a dosage that does not exceed 40 milligrams of elemental zinc.
21. The nutrient formulation of claim 12 , wherein the user has macular degeneration and a lens-related disorder.
22. The nutrient formulation of claim 21 , wherein the lens-related disorder is presbyopia.
23. The nutrient formulation of claim 12 , further comprising at least one of taurine, carnitine and carnosine.
24. The nutrient formulation of claim 12 , further comprising glutathione boosters.